GRM2
Metabotropic glutamate receptor 2
Also known as: GPRC1B, GRM2_HUMAN, mGlu2, MGLUR2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q14416
- Gene
- GRM2
- Ensembl
- ENSG00000164082
- Chromosome
- 3
- Canonical length
- 872 aa
- Protein class
- G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2017]
Canonical amino-acid sequenceUniProt
872 residues, UniProt reviewed canonical sequence.
>Q14416|GRM2
1 MGSLLALLAL LLLWGAVAEG PAKKVLTLEG DLVLGGLFPV HQKGGPAEDC GPVNEHRGIQ
61 RLEAMLFALD RINRDPHLLP GVRLGAHILD SCSKDTHALE QALDFVRASL SRGADGSRHI
121 CPDGSYATHG DAPTAITGVI GGSYSDVSIQ VANLLRLFQI PQISYASTSA KLSDKSRYDY
181 FARTVPPDFF QAKAMAEILR FFNWTYVSTV ASEGDYGETG IEAFELEARA RNICVATSEK
241 VGRAMSRAAF EGVVRALLQK PSARVAVLFT RSEDARELLA ASQRLNASFT WVASDGWGAL
301 ESVVAGSEGA AEGAITIELA SYPISDFASY FQSLDPWNNS RNPWFREFWE QRFRCSFRQR
361 DCAAHSLRAV PFEQESKIMF VVNAVYAMAH ALHNMHRALC PNTTRLCDAM RPVNGRRLYK
421 DFVLNVKFDA PFRPADTHNE VRFDRFGDGI GRYNIFTYLR AGSGRYRYQK VGYWAEGLTL
481 DTSLIPWASP SAGPLPASRC SEPCLQNEVK SVQPGEVCCW LCIPCQPYEY RLDEFTCADC
541 GLGYWPNASL TGCFELPQEY IRWGDAWAVG PVTIACLGAL ATLFVLGVFV RHNATPVVKA
601 SGRELCYILL GGVFLCYCMT FIFIAKPSTA VCTLRRLGLG TAFSVCYSAL LTKTNRIARI
661 FGGAREGAQR PRFISPASQV AICLALISGQ LLIVVAWLVV EAPGTGKETA PERREVVTLR
721 CNHRDASMLG SLAYNVLLIA LCTLYAFKTR KCPENFNEAK FIGFTMYTTC IIWLAFLPIF
781 YVTSSDYRVQ TTTMCVSVSL SGSVVLGCLF APKLHIILFQ PQKNVVSHRA PTSRFGSAAA
841 RASSSLGQGS GSQFVPTVCN GREVVDSTTS SLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GRM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 4.6 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 4.6 nTPM
- cerebellum: 1.5 nTPM
- hippocampal formation: 1.1 nTPM
- hypothalamus: 1.1 nTPM
- amygdala: 0.6 nTPM
- testis: 0.6 nTPM
Single-cell type
- brain excitatory neurons: 13 nCPM
- retinal amacrine cells: 9.7 nCPM
- other brain neurons: 5.1 nCPM
- cone photoreceptor cells: 4.1 nCPM
- early primary spermatocytes: 3.4 nCPM
- brain inhibitory neurons: 1.7 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- pons: 21 nTPM
- cerebral cortex: 13 nTPM
- basal ganglia: 12 nTPM
- medulla oblongata: 9.8 nTPM
- hippocampal formation: 9.1 nTPM
- white matter: 9.1 nTPM
ReferencesPubMed · IEDB
Publications for GRM2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2.
2020 · Neurol Neuroimmunol Neuroinflamm · RCR 2.4 · 44 citations - A Case Series of Anti-Metabotropic Glutamate Receptor 2 Antibody-Related Diseases with Distinct Neurological Involvement.
2025 · Immunotargets Ther · 3 citations - Case Report: Coexistence of anti-LGI1 and anti-mGluR2 antibodies in an autoimmune encephalitis patient.
2025 · Front Immunol · 3 citations - Overlapping syndrome with concomitant mGluR2-Ab and GFAP-Ab: A case report.
2025 · Clin Immunol · 1 citations - Identifying Neurological Autoantibodies in COVID-19: mGluR2 as a Marker of Immune Dysregulation During the Omicron Outbreak in China.
2025 · J Med Virol
Show 1 more
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.49
- gnomAD pLI
- 0.12
- gnomAD missense Z
- 2.37
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- behavioral response to nicotine
- cellular response to stress
- chemical synaptic transmission
- G protein-coupled glutamate receptor signaling pathway
- gene expression
- glutamate secretion
- intracellular glutamate homeostasis
- long-term synaptic depression
- negative regulation of adenylate cyclase activity
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- presynaptic modulation of chemical synaptic transmission
- regulation of dopamine secretion
- regulation of glutamate secretion
- regulation of response to drug
- regulation of synaptic transmission, glutamatergic
- response to cocaine
Molecular functions
- calcium channel regulator activity
- G protein-coupled receptor activity
- glutamate receptor activity
- group II metabotropic glutamate receptor activity
- scaffold protein binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- GPCR, family 3, metabotropic glutamate receptor
- GPCR, family 3
- Receptor, ligand binding region
- GPCR, family 3, nine cysteines domain
- GPCR family 3, C-terminal
- GPCR, family 3, conserved site
- Periplasmic binding protein-like I
- GPCR, family 3, nine cysteines domain superfamily
- Metabotropic Glutamate Receptor
- 7 transmembrane sweet-taste receptor of 3 GCPR
- Receptor family ligand binding region
- Nine Cysteines Domain of family 3 GPCR
- GPCR, family 3, metabotropic glutamate receptor 2
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GRM2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GRM2 as an antibody target. Whether an autoantibody or antibody against GRM2 could matter depends on whether native GRM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GRM2 is annotated at the cell surface, where native GRM2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GRM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...